Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2019 4
2020 2
2021 1
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
Favorskaya IA, Shcheblyakov DV, Esmagambetov IB, Dolzhikova IV, Alekseeva IA, Korobkova AI, Voronina DV, Ryabova EI, Derkaev AA, Kovyrshina AV, Iliukhina AA, Botikov AG, Voronina OL, Egorova DA, Zubkova OV, Ryzhova NN, Aksenova EI, Kunda MS, Logunov DY, Naroditsky BS, Gintsburg AL. Favorskaya IA, et al. Among authors: alekseeva ia. Front Immunol. 2022 Feb 24;13:822159. doi: 10.3389/fimmu.2022.822159. eCollection 2022. Front Immunol. 2022. PMID: 35281053 Free PMC article.
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21.
Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Karlowsky JA, et al. Among authors: alekseeva i. JAC Antimicrob Resist. 2023 Aug 11;5(4):dlad098. doi: 10.1093/jacamr/dlad098. eCollection 2023 Aug. JAC Antimicrob Resist. 2023. PMID: 37577157 Free PMC article.
Evaluation of in vitro activity of ceftolozane/tazobactam and comparators against recent clinical bacterial isolates, and genomics of Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli isolates that demonstrated resistance to ceftolozane/tazobactam: data from Kuwait and Oman.
Alfouzan W, Dhar R, Mohsin J, Khamis F, Mokaddas E, Abdullah A, Mustafa AS, Otero A, Wanis P, Matar SH, Khalil S, Alekseeva I, Young K. Alfouzan W, et al. Among authors: alekseeva i. JAC Antimicrob Resist. 2022 Apr 21;4(2):dlac035. doi: 10.1093/jacamr/dlac035. eCollection 2022 Apr. JAC Antimicrob Resist. 2022. PMID: 35465239 Free PMC article.
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Lob SH, et al. Among authors: alekseeva i. Int J Infect Dis. 2022 Dec;125:250-257. doi: 10.1016/j.ijid.2022.10.014. Epub 2022 Oct 14. Int J Infect Dis. 2022. PMID: 36244599 Free article.
Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU.
Moise PA, Gonzalez M, Alekseeva I, Lopez D, Akrich B, DeRyke CA, Chen WT, Pavia J, Palermo B, Hackel M, Motyl M. Moise PA, et al. Among authors: alekseeva i. JAC Antimicrob Resist. 2021 Feb 19;3(1):dlaa129. doi: 10.1093/jacamr/dlaa129. eCollection 2021 Mar. JAC Antimicrob Resist. 2021. PMID: 34223078 Free PMC article.
14 results